PrintThe Burrill Report
June 28, 2013
http://www.burrillreport.com/article-biggest_advancers_and_decliners_first_half_of_2013.html
DATA CENTER
Biggest Advancers and Decliners First Half of 2013
Life sciences stocks that began the year with a minimum price of $1 per share.[Please login to post comments]
- Will Harlem Be the Next Hotspot for Innovation?
Podcast: July 8, 2013 Read More - Cardio3 BioSciences Goes Public
Belgian biotech’s IPO brings to 30 the number of completed life sciences initial public offerings so far in 2013. Read More - California Life Sciences Companies Lead in Venture Financings
Golden State startups account for 38 percent of total raised in first half of 2013. Read More - SEC Investigates Call Options Trading of Onyx Pharmaceuticals Stock
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More - Biogen licenses Myelin Repair Foundation Tech in Fight Against MS
MRF mouse model provides unique characteristics for development of wide range of therapeutics. Read More - Genentech Strikes Immunotherapy Deal with Immunocore
Biotech’s platform generates modified T-cell receptors as drugs that target cancer and viral infection. Read More - FDA Gives Antibacterial Drug Developers New Guidance
To address growing drug resistance, agency seeks new mechanisms of action, ability to neutralize resistance. Read More - Eisai Suspends Sales of Anti-epileptic Drug Fycompa In Germany
Japanese drugmaker says assessment falls short of recognizing its product's value. Read More - Unique Treatment for Type 1 Diabetes Shows Promise
Novel reverse DNA vaccine improves pancreas function. Read More - SECA Presntation
Read More
.gif)
